论文部分内容阅读
目的探讨瑞舒伐他汀对急性脑梗死患者血浆超敏C反应蛋白和脂蛋白相关磷脂酶A2的影响。方法 86例急性脑梗死患者随机分为两组,对照组40例,治疗组46例;对照组采用常规治疗,治疗组在常规治疗的基础上加用瑞舒伐他汀20mg,1次/d,口服,两组共治疗30d。治疗前后测定患者血浆超敏C反应蛋白(hs-CRP)和脂蛋白相关磷脂酶A2(Lp-PLA2)的浓度。结果两组治疗后均明显降低血浆hs-CRP和LP-PLA2的表达,并且治疗组降低二者更明显(P<0.05)。两组均未出现严重的不良反应。结论瑞舒伐他汀可以明显降低急性脑梗死患者血浆hs-CRP和Lp-PLA2的表达。
Objective To investigate the effect of rosuvastatin on plasma high sensitivity C-reactive protein and lipoprotein-associated phospholipase A2 in patients with acute cerebral infarction. Methods Eighty-six patients with acute cerebral infarction were randomly divided into two groups: control group (n = 40) and treatment group (n = 46). The control group received routine treatment. The treatment group received rosuvastatin 20 mg once daily, Oral, two groups were treated for 30 days. The levels of plasma hs-CRP and Lp-PLA2 in patients before and after treatment were measured. Results After treatment, the expression of hs-CRP and LP-PLA2 in both groups were significantly lower than those in the control group (P <0.05). No serious adverse reactions occurred in both groups. Conclusion Rosuvastatin can significantly reduce the expression of hs-CRP and Lp-PLA2 in patients with acute cerebral infarction.